Table 1: Parkinson’s Disease.

In this table, pre-clinical studies from between 1995 and 2018 which specifically investigated stem cell therapy with intracerebral transplantation are referenced. Although many PD clinical trials are underway, data is not yet published and is therefore not included in this table. In summary, these milestone discoveries indicate that transplantation of NSCs, ESCs, and iPSC-derived DA neurons ameliorates Parkinsonian dyskinesia and promotes neurogenesis in rat models of PD.

Authors	Model	Cell Type	Cell Quantity	Outcomes
Nikkhah et al., 1995	6-OHDA-lesioned rats	E14 rat fetal-derived DA rick cells	Two injections of 4×104	Neurogenesis
Yasuhara et al., 2006a	6-OHDA-lesioned rats	Human fetal-derived NSC	2×106 cells	Neuroprotection, Neurogenesis, Behavioral amelioration
Kriks et al., 2011	6-OHDA-lesioned mice, rats and monkeys	Human ESC and iPSC-derived DA neurons	1.5×105 for mice, 2.5×105 for rats, 7.5×106 for monkeys.	Neuroprotection, Neurogenesis
Kirkeby et al., 2012	6-OHDA-lesioned rats	Human ESC and fetal-derived NSC	Two injections of 1.5×105 cells at d10, 3×105 cells at d16	Neurogenesis, Behavioral amelioration
L’episcopo et al., 2018	MPTP-injected mice	Mouse NSC	1×105 cells	Neuroprotection, Immunomodul ati on

6-OHDA – 6-hydroxydopamine; DA – dopamine; NSC – neural stem cells; ESC – embryonic stem cells; iPSC – induced pluripotent stem cells; PD – Parkinson’s disease